Can-Fite BioPharma Ltd.
CANF
$1.23
-$0.03-2.38%
AMEX
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | 15.48% | -19.39% | -21.32% | -18.73% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 15.48% | -19.39% | -21.32% | -18.73% | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | 15.48% | -19.39% | -21.32% | -18.73% | |
| SG&A Expenses | 5.40% | 22.20% | -12.59% | -9.85% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 10.46% | 11.36% | -39.36% | -26.16% | |
| Operating Income | -10.03% | -14.74% | 40.51% | 26.70% | |
| Income Before Tax | -18.73% | -18.47% | 45.28% | 25.62% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -18.73% | -18.47% | 45.28% | 25.62% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -18.73% | -18.47% | 45.28% | 25.62% | |
| EBIT | -10.03% | -14.74% | 40.51% | 26.70% | |
| EBITDA | -10.09% | -14.97% | 40.57% | 26.73% | |
| EPS Basic | 27.27% | 21.43% | 70.27% | 50.00% | |
| Normalized Basic EPS | 28.57% | 22.22% | 66.67% | 51.28% | |
| EPS Diluted | 27.27% | 21.43% | 70.27% | 50.00% | |
| Normalized Diluted EPS | 28.57% | 22.22% | 66.67% | 51.28% | |
| Average Basic Shares Outstanding | 70.53% | 48.64% | 81.91% | 48.93% | |
| Average Diluted Shares Outstanding | 70.53% | 48.64% | 81.91% | 48.93% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |